EpiVax, Inc. - Informatics and Immunology
  • Our Company
    • Company Overview
    • Corporate Responsibility
    • Mission, Vision & Values
    • Team
    • Careers
    • Contact Us
  • Pipeline
    • Pipeline Overview
    • BioDefense Vaccines
    • Tregitope: Immunomodulation Power Tool
    • Deimmunization Projects
  • Vaccine Services
    • Vaccine Services
    • iVAX: Web-based Vaccine Design
    • PreVAX Analysis
    • EpiCC
  • Immunogenicity Assessment
    • Immunogenicity Assessment Overview
    • ISPRI Web-based Immunogenicity Assessment
    • PreDeFT Analysis
    • High Throughput Immunogenicity Analysis
    • PANDA Screening
    • ISPRI for Host Cell Proteins
    • Deimmunization
    • Trusted Expert Advice (TEA) Consulting Services
  • Lab Services
    • Lab Services Overview
    • HLA Binding Assays
    • T Cell Assays
  • Press Room
    • Press Room
    • Events
      • Webinars
    • Publication & Poster Search
    • Client Testimonials
    • Thinking Out Loud (Blog)
    • Recipes For Success (Podcast)
  • Contact Us
Select Page
Tumor homology with self as a biomarker for response to checkpoint inhibitor therapy

Tumor homology with self as a biomarker for response to checkpoint inhibitor therapy

by Corey Iacono | Nov 17, 2022

EpiVaxTx_SITC22_Melanoma_28Oct22_56Wx31.5H    
Multi-step screening of neoantigens’ HLA- and TCR-interfaces improves prediction of survival

Multi-step screening of neoantigens’ HLA- and TCR-interfaces improves prediction of survival

by Riley Nolan | May 13, 2021

Immunoinformatic Analysis of Pancreatic Cancer Mutanomes: Impact of Regulatory T Cell Neo-Epitopes on Patient Outcome

Immunoinformatic Analysis of Pancreatic Cancer Mutanomes: Impact of Regulatory T Cell Neo-Epitopes on Patient Outcome

by Annie De Groot | May 14, 2019

EpiVax_Oncology_NYAS_08May19_35Wx25H
Computational Identification of Self-Like Neoantigens Enables the Rapid Design of Immunogenic Cancer Vaccines

Computational Identification of Self-Like Neoantigens Enables the Rapid Design of Immunogenic Cancer Vaccines

by Annie De Groot | Apr 8, 2019

EpiVax_Oncology_TRI-CON_CT26_04Mar19_32w44h
From infectious disease to personalized cancer vaccines: Regulatory T cell epitopes determine patient outcomes and suppress neoantigen responses

From infectious disease to personalized cancer vaccines: Regulatory T cell epitopes determine patient outcomes and suppress neoantigen responses

by Annie De Groot | Nov 6, 2018

EpiVax_Oncology_Ancer_SITC_05Nov18_39Wx35H
« Older Entries

Recent Posts

  • Hey Hey! Hallo! This is a two-way conversation!
  • EpiVax CEO Speaks at the Hwasun International Vaccine and Immunotherapy Forum
  • Visits from the FBI and SEC… and Fearless Science
  • Dreaming of Peptides (and Hello from Tokyo!)
  • Streamlining Generic Drug Immunogenicity Evaluation: EpiVax’s “PANDA” Approach

Categories

  • EpiVax Immunoncology
  • Events
  • Featured
  • News
  • Recipes for Success – Vlog
  • Thinking Out Loud -Blog
  • Uncategorized
  • Webinars

Discover

  • Vaccine Services
  • Immunogenicity Assessment
  • Deimmunization
  • Lab Services
  • Pipeline

About

  • Our Company
  • Press Room
  • Events
  • Publication & Poster Search
  • Thinking Out Loud (Blog)
  • Contact Us

Connect

© 2023 EpiVax, Inc. – Informatics and Immunology, All rights reserved. Privacy Policy • 188 Valley Street, Suite 424, Providence, RI 02909 • ph: 401.272.2123 • fax: 401.272.7562